Efficacy and safety of Panax ginseng berry extract on glycemic control: A 12-wk randomized, double-blind, and placebo-controlled clinical trial

Journal of Ginseng Research

Volumn 42, Issue 1, 2018, Pages 90-97

  Choi, Han Seok ^a   Kim, Sunmi ^b   Kim, Min Jung ^c   Kim, Myung Sunny ^c   Kim, Juewon ^b   Park, Chan Woong ^b   Seo, Daebang ^b   Shin, Song Seok ^b   Oh, Sang Woo ^a  

^a Dongguk University Ilsan Hospital   (South Korea)

^b AmorePacific Corporation   (South Korea)

^c Korea Food Research Institute   (South Korea)

Author keywords

antihyperglycemic effects; clinical trial; glucose metabolism; oral glucose tolerance test; Panax ginseng berry

Indexed keywords

ALANINE; ANTIDIABETIC AGENT; CARNITINE; CREATINE; GINSENG EXTRACT; GLUCOSE; GLUTAMINE; GLYCEROPHOSPHORYLCHOLINE; LEUCINE; LINOLEOYL CARNITINE; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLETHANOLAMINE; METHIONINE; PHENYLALANINE; PHENYLPYRUVIC ACID; PHOSPHATIDYLETHANOLAMINE; SUCCINIC ACID; UNCLASSIFIED DRUG; VALINE; XANTHINE;

ADULT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BERRY; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ISOLATION; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; GINSENG; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MIDDLE AGED; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UROLITHIASIS;

EID: 85011822015     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgr.2017.01.003     Document Type: Article

References (41)

1. Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87 (2010), 4–14.
2. Ha, K.H., Kim, D.J., Trends in the diabetes epidemics in Korea. Endocrinol Metab 30 (2015), 142–146.
3. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care 25 (2002), 742–749.
4. Bi, X., Xia, X., Mou, T., Jiang, B., Fan, D., Wang, P., Liu, Y., Hou, Y., Zhao, Y., Anti-tumor activity of three ginsenoside derivatives in lung cancer is associated with Wnt/β-catenin signaling inhibition. Eur J Pharmacol 742 (2014), 145–152.
5. Ramesh, T., Kim, S.W., Sung, J.H., Hwang, S.Y., Sohn, S.H., Yoo, S.K., Kim, S.K., Effect of fermented Panax ginseng extract (GINST) on oxidative stress and antioxidant activities in major organs of aged rats. Exp Gerontol 47 (2012), 77–84.
6. Hong, C.E., Lyu, S.Y., Anti-inflammatory and anti-oxidative effects of Korean Red Ginseng extract in human keratinocytes. Immune Netw 11 (2011), 42–49.
7. Jung, J.W., Kang, H.R., Ji, G.E., Park, M.S., Song, W.J., Kim, M.H., Kwon, J.W., Kim, T.W., Park, H.W., Cho, S.H., Min, K.U., Therapeutic effects of fermented red ginseng in allergic rhinitis: a randomized, double-blind, placebo-controlled study. Allergy Asthma Immunol Res 3 (2011), 103–110.
8. Kim, K., Kim, H.Y., Korean Red Ginseng stimulates insulin release from isolated rat pancreatic islets. J Ethnopharmacol 120 (2008), 190–195.
9. Kim, J.J., Xiao, H., Tan, Y., Wang, Z.Z., Paul Seale, J., Qu, X., The effects and mechanism of saponins of Panax notoginseng on glucose metabolism in 3T3-L1 cells. Am J Chin Med 37 (2009), 1179–1189.
10. Kimura, M., Waki, I., Chujo, T., Kikuchi, T., Hiyama, C., Yamazaki, K., Tanaka, O., Effects of hypoglycemic components in ginseng radix on blood insulin level in alloxan diabetic mice and on insulin release from perfused rat pancreas. J Pharm Dyn 4 (1981), 410–417.
11. Yokozawa, T., Kobayashi, T., Oura, H., Kawashima, Y., Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb2 in straptozotocin-diabetic rats. Chem Pharm Bull 33 (1985), 869–872.
12. Yun, S.N., Moon, S.J., Ko, S.K., Im, B.O., Chung, S.H., Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice. Arch Pharm Res 27 (2004), 790–796.
13. Kimura, I., Nakashima, N., Sugihara, Y., Fu-jun, C., Kimura, M., The antihyperglycaemic blend effect of traditional Chinese medicine byakko-ka-ninjin-to on alloxan and diabetic KK-CA(y) mice. Phytother Res 13 (1999), 484–488.
14. Attele, A.S., Zhou, Y.P., Xie, J.T., Wu, J.A., Zhang, L., Dey, L., Pugh, W., Rue, P.A., Polonsky, K.S., Yuan, C.S., Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes 51 (2002), 1851–1858.
15. Xie, J.T., Zhou, Y.P., Dey, L., Attele, A.S., Wu, J.A., Gu, M., Polonsky, K.S., Yuan, C.S., Ginseng berry reduces blood glucose and body weight in db/db mice. Phytomedicine 9 (2002), 254–258.
16. Yuan, H.D., Kin, S.J., Quan, H.Y., Huang, B., Chung, S.H., Ginseng leaf extract prevents high fat diet-induced hyperglycemia and hyperlipidemia through AMPK activation. J Ginseng Res 34 (2010), 369–375.
17. Yuan, H.D., Shin, E.J., Chung, S.H., Anti-diabetic effect and mechanism of Korean red ginseng in C57BL/KsJ db/db mice. J Ginseng Res 32 (2008), 187–193.
18. Lee, H.J., Lee, Y.H., Park, S.K., Kang, E.S., Kim, H.J., Lee, Y.C., Choi, C.S., Park, S.E., Ahn, C.W., Cha, B.S., et al. Korean Red Ginseng (Panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in Otsuka Long–Evans Tokushima fatty rats. Metabolism 58 (2009), 1170–1177.
19. Liu, Z., Wang, L.J., Li, X., Hu, J.N., Chen, Y., Ruan, C.C., Sun, G.Z., Hypoglycemic effects of malonyl-ginsenosides extracted from roots of Panax ginseng on streptozotocin-induced diabetic mice. Phytother Res 23 (2009), 1426–1430.
20. Sotaniemi, E.A., Haapakoski, E., Rautio, A., Ginseng therapy in non-insulin dependent diabetic patients. Diabetes Care 18 (1995), 1373–1375.
21. Vuksan, V., Sievenpiper, J.L., Koo, V.Y.Y., Francis, T., Beljan-Zdravkovic, U., Xu, Z., Vidgen, E., American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med 160 (2000), 1009–1013.
22. Vuksan, V., Sung, M.K., Sievenpiper, J.L., Stavro, P.M., Jenkins, A.L., Di Buono, M., Lee, K.S., Leiter, L.A., Nam, K.Y., Arnason, J.T., et al. Korean Red Ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebocontrolled study of efficacy and safety. Nutr Metab Cardiovasc Dis 18 (2008), 46–56.
23. Dey, L., Xie, J.T., Wang, A., Wu, J., Maleckar, S.A., Yuan, C.S., Anti-hyperglycemic effects of ginseng: comparison between root and berry. Phytomedicine 10 (2003), 600–605.
24. Kim, Y.K., Yoo, D.S., Xu, H., Park, N.I., Kim, H.H., Choi, J.E., Park, S.U., Ginsenoside content of berries and roots of three typical Korean ginseng (Panax ginseng) cultivars. Nat Prod Commun 4 (2009), 903–906.
25. Kim, C.K., Cho, D.H., Lee, K.S., Lee, D.K., Park, C.W., Kim, W.G., Lee, S.J., Ha, K.S., Taeg, O.G., Kwon, Y.G., et al. Ginseng berry extract prevents atherogenesis via anti-inflammatory action by upregulating phase II gene expression. Evid Based Complement Alternat Med, 2012, 2012, 490301.
26. Attele, A.S., Wu, J.A., Yuan, C.S., Ginseng pharmacology: multiple constituents and multiple actions. Biochem Pharmacol 58 (1999), 1685–1693.
27. Ji, Q.C., Harkey, M.R., Henderson, G.L., Gershwin, M.E., Stern, J.S., Hackman, R.M., Quantitative determination of ginsenosides by high-performance liquid chromatography-tandem mass spectrometry. Phytochem Anal 12 (2001), 320–326.
28. Xie, J.T., Mehendale, S.R., Li, X., Quigg, R., Wang, X., Wang, C.Z., Wu, J.A., Aung, H.H., A Rue, P., Bell, G.I., et al. Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochim Biophys Acta 1740 (2005), 319–325.
29. Ma, S.W., Benzie, I.F., Chu, T.T., Fok, B.S., Tomlinson, B., Critchley, L.A., Effect of Panax ginseng supplementation on biomarkers of glucose tolerance, antioxidant status and oxidative stress in type 2 diabetic subjects: results of a placebo-controlled human intervention trial. Diabetes Obes Metab 10 (2008), 1125–1127.
30. Reay, J.L., Scholey, A.B., Milne, A., Fenwick, J., Kennedy, D.O., Panax ginseng has no effect on indices of glucose regulation following acute or chronic ingestion in healthy volunteers. Br J Nutr 101 (2009), 1673–1678.
31. Reeds, D.N., Patterson, B.W., Okunade, A., Holloszy, J.O., Polonsky, K.S., Klein, S., Ginseng and ginsenoside Re do not improve β-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. Diabetes Care 34 (2011), 1071–1076.
32. Oh, M.R., Park, S.H., Kim, S.Y., Back, H.I., Kim, M.G., Jeon, J.Y., Ha, K.C., Na, W.T., Cha, Y.S., Park, B.H., Park, T.S., Chae, S.W., Postprandial glucose-lowering effects of fermented red ginseng in subjects with impaired fasting glucose or type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. BMC Complement Altern Med, 14, 2014, 237.
33. Bang, H., Kwak, J.H., Ahn, H.Y., Shin, D.Y., Lee, J.H., Korean red ginseng improves glucose control in subjects with impaired fasting glucose, impaired glucose tolerance, or newly diagnosed type 2 diabetes mellitus. J Med Food 17 (2014), 128–134.
34. Yuan, H.D., Kim, J.T., Kim, S.H., Chung, S.H., Ginseng and diabetes: the evidences from in vitro, animal and human studies. J Ginseng Res 36 (2012), 27–39.
35. Park, E.Y., Kim, H.J., Kim, Y.K., Park, S.U., Choi, J.E., Cha, J.Y., Jun, H.S., Increase in insulin secretion induced by Panax ginseng berry extracts contributes to the amelioration of hyperglycemia in streptozotocin-induced diabetic mice. J Ginseng Res 36 (2012), 153–160.
36. Seo, E., Kim, S., Lee, S.J., Oh, B.C., Jun, H.S., Ginseng berry extract supplementation improves age-related decline of insulin signaling in mice. Nutrients 7 (2015), 3038–3053.
37. Jung, H.S., Clinical implications of glucose variability: chronic complications of diabetes. Endocrinol Metab 30 (2015), 167–174.
38. Ceriello, A., Ihnat, M., “Glycaemic variability:” a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 27 (2010), 862–867.
39. Cavalot, F., Petrelli, A., Traversa, M., Bonomo, K., Fiora, E., Conti, M., Anfossi, G., Costa, G., Trovati, M., Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91 (2006), 813–819.
40. Chiasson, J.L., Josse, R.G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003), 486–494.
41. Hanefeld, M., Cagatay, M., Petrowitsch, T., Neuser, D., Petzinna, D., Rupp, M., Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25 (2004), 10–16.